Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Stock Crosses Below Fifty Day Moving Average of $0.29

Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE – Get Rating)’s share price passed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $0.29 and traded as low as $0.22. Ampio Pharmaceuticals shares last traded at $0.22, with a volume of 124,662 shares trading hands.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on Ampio Pharmaceuticals in a research note on Friday. They set a “sell” rating on the stock.

Ampio Pharmaceuticals Stock Down 26.7 %

The stock has a market cap of $3.32 million, a PE ratio of -0.12 and a beta of 1.48. The business has a 50 day moving average price of $0.29 and a 200 day moving average price of $0.20.

Institutional Trading of Ampio Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. Two Sigma Advisers LP boosted its stake in shares of Ampio Pharmaceuticals by 304.3% in the third quarter. Two Sigma Advisers LP now owns 432,216 shares of the specialty pharmaceutical company’s stock worth $26,000 after buying an additional 325,300 shares during the last quarter. Vanguard Group Inc. raised its holdings in Ampio Pharmaceuticals by 20.0% in the 3rd quarter. Vanguard Group Inc. now owns 9,954,092 shares of the specialty pharmaceutical company’s stock worth $602,000 after purchasing an additional 1,662,127 shares during the period. Shilanski & Associates Inc. acquired a new position in Ampio Pharmaceuticals in the 3rd quarter worth about $57,000. Price T Rowe Associates Inc. MD raised its holdings in Ampio Pharmaceuticals by 73.5% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 394,100 shares of the specialty pharmaceutical company’s stock worth $66,000 after purchasing an additional 166,979 shares during the period. Finally, Millennium Management LLC raised its holdings in Ampio Pharmaceuticals by 998.6% in the 2nd quarter. Millennium Management LLC now owns 2,035,413 shares of the specialty pharmaceutical company’s stock worth $342,000 after purchasing an additional 1,850,138 shares during the period. Hedge funds and other institutional investors own 19.82% of the company’s stock.

About Ampio Pharmaceuticals

(Get Rating)

Ampio Pharmaceuticals, Inc operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease.